EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

underscores Novo Nordisk's drive to boost output of Wegovy, a once-weekly injection. After the deal closes, Novo Holdings ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

A summary of current health news details EU regulators probing Novo Nordisk's $16.5 billion Catalent takeover, Amgen's ...

BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

Under the current plan, Novo Nordisk is in line to purchase three Catalent fill-finish facilities from Novo Holdings for $11 billion after the closure of Novo Holdings' Catalent purchase.

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. A dozen consumer groups and trade ...